BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 32243578)

  • 1. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review.
    Dupré A; Michot JM; Schoeffler A; Frumholtz L; Baroudjian B; Delyon J; Lebbe C; Lambotte O
    Br J Haematol; 2020 Jun; 189(5):985-992. PubMed ID: 32243578
    [No Abstract]   [Full Text] [Related]  

  • 2. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors.
    Azari AE; Stratton R; Singh A
    Rheumatology (Oxford); 2021 May; 60(5):e167-e168. PubMed ID: 33280022
    [No Abstract]   [Full Text] [Related]  

  • 3. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
    Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
    Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
    Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
    [No Abstract]   [Full Text] [Related]  

  • 5. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
    Fukumoto T; Horita N
    Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
    Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
    J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis.
    Isidro RA; Ruan AB; Gannarapu S; Raj D; Rahma O; Grover S; Srivastava A
    Histopathology; 2021 Mar; 78(4):532-541. PubMed ID: 32931028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy.
    Holmes Z; Courtney A; Hiong A
    BMJ Case Rep; 2022 Aug; 15(8):. PubMed ID: 35948362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor-associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation.
    Chanson N; Ramos-Casals M; Pundole X; Suijkerbuijk K; José de Barros E Silva M; Lidar M; Benesova K; Leipe J; Acar-Denizli N; Pradère P; Michot JM; Voisin AL; Suárez-Almazor ME; Radstake TRD; Fernandes Moça Trevisani V; Schulze-Koops H; Melin A; Robert C; Mariette X; Baughman RP; Lambotte O; ; ; ; ; ;
    Eur J Cancer; 2021 Nov; 158():208-216. PubMed ID: 34452793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
    Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
    Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
    [No Abstract]   [Full Text] [Related]  

  • 11. Sicca syndrome following immune checkpoint inhibition.
    Mavragani CP; Moutsopoulos HM
    Clin Immunol; 2020 Aug; 217():108497. PubMed ID: 32531346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.
    Bishu S; Melia J; Sharfman W; Lao CD; Fecher LA; Higgins PDR
    Gastroenterology; 2021 Feb; 160(3):932-934.e3. PubMed ID: 33096100
    [No Abstract]   [Full Text] [Related]  

  • 13. Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors.
    Kurozumi A; Takahashi H; Watanabe T; Iwasaki Y
    Thorac Cancer; 2021 May; 12(10):1625-1628. PubMed ID: 33783978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rare and fatal complication of immune checkpoint inhibition: a case report of haemophagocytic lymphohistiocytosis with severe lichenoid dermatitis.
    Choi S; Zhou M; Bahrani E; Martin BA; Ganjoo KN; Zaba LC
    Br J Haematol; 2021 Jun; 193(6):e44-e47. PubMed ID: 33954981
    [No Abstract]   [Full Text] [Related]  

  • 15. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
    Yoshida S; Shiraishi K; Mito T; Sayama K
    Clin Exp Dermatol; 2020 Oct; 45(7):908-911. PubMed ID: 32394515
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunotherapy in colorectal cancer with mismatch repair deficiency.
    Overman MJ
    Clin Adv Hematol Oncol; 2019 May; 17(5):265-267. PubMed ID: 31188802
    [No Abstract]   [Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitor-Induced Ptosis in a Patient With Prostate Cancer.
    Williams KJ; Allen RC
    J Neuroophthalmol; 2021 Mar; 41(1):e71-e72. PubMed ID: 32235233
    [No Abstract]   [Full Text] [Related]  

  • 18. Effective Treatment of a Melanoma Patient with Hemophagocytic Lymphohistiocytosis after Nivolumab and Ipilimumab Combined Immunotherapy.
    Pacholczak-Madej R; Grela-Wojewoda A; Lompart J; Żuchowska-Vogelgesang B; Ziobro M
    Prague Med Rep; 2022; 123(1):35-42. PubMed ID: 35248163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse Events.
    Takai R; Funakoshi Y; Suto H; Nagatani Y; Imamura Y; Toyoda M; Yakushijin K; Kiyota N; Harada KI; Yamashita K; Kakeji Y; Minami H
    Anticancer Res; 2021 Feb; 41(2):1021-1026. PubMed ID: 33517310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
    Nada A; Bhat R; Cousins J
    Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.